This is an article from the National Institutes of Health that discusses the opportunities and challenges for making genomic (sequencing all 3 billion base pairs) or exomic (sequencing the 1-2% of the genome that contains the 20,000 genes that encode proteins) a routine test in the doctor’s office. The study was conducted by the National Human Genomic Research Institute – see report. Continue reading
Category Archives: Genetics
Epigenetic-modulation in myelodysplastic syndrome – DNA methylation and histone acetylation
Epigenetic regulation is critical for gene expression. Epigenetic pathways are frequently dysregulated in cancer, which can lead to suppression of tumor suppressor genes and expression of oncogenes. Continue reading
IDH1 and IDH2 inhibitors
IDH1 and IDH2 are enzymes in the Krebs Cycle of glucose metabolism – IDH1 (AG-120) is active in the cyotplasm and IDH2 (AG-221) is active in the mitochondria. Phase 1 clinical studies of these compounds are underway. Continue reading
FDA Clinical Hold lifted on telomerase inhibitor
In clinical trials, “clinical holds” are imposed by the FDA when toxicities emerge that are unexpected, either new toxicities that have not been seen before, (or were not anticipated) or increased severity of known or anticipated side effects. The hold allows the FDA to assess the data, demand more data from the sponsoring companies, and make appropriate changes in the study protocol… Continue reading